214 related articles for article (PubMed ID: 32323484)
41. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
42. Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.
McDermott RL; Armstrong JG; Thirion P; Dunne M; Finn M; Small C; Byrne M; O'Shea C; O'Sullivan L; Shannon A; Kelly E; Hacking DJ
Radiother Oncol; 2018 May; 127(2):253-258. PubMed ID: 29548561
[TBL] [Abstract][Full Text] [Related]
43. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
[TBL] [Abstract][Full Text] [Related]
44. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
45. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
47. Radiation-Induced Lung Density Changes on CT Scan for NSCLC: No Impact of Dose-Escalation Level or Volume.
Defraene G; La Fontaine M; van Kranen S; Reymen B; Belderbos J; Sonke JJ; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):642-650. PubMed ID: 30244882
[TBL] [Abstract][Full Text] [Related]
48. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
Socinski MA; Rosenman JG; Halle J; Schell MJ; Lin Y; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
Cancer; 2001 Sep; 92(5):1213-23. PubMed ID: 11571735
[TBL] [Abstract][Full Text] [Related]
49. A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer.
Yamamoto N; Miyamoto T; Nakajima M; Karube M; Hayashi K; Tsuji H; Tsujii H; Kamada T; Fujisawa T
J Thorac Oncol; 2017 Apr; 12(4):673-680. PubMed ID: 28007628
[TBL] [Abstract][Full Text] [Related]
50. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
51. Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
Binkley MS; Hiniker SM; Chaudhuri A; Maxim PG; Diehn M; Loo BW; Shultz DB
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):808-15. PubMed ID: 26831903
[TBL] [Abstract][Full Text] [Related]
52. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
53. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer.
Armstrong J; McGibney C
Radiother Oncol; 2000 Aug; 56(2):157-67. PubMed ID: 10927134
[TBL] [Abstract][Full Text] [Related]
54. Analysis of dose distribution in the 'Rind'--a volume outside the PTV--in 3-dimensional conformal radiation therapy of non-small cell lung cancer.
McGibney C; Holmberg O; McClean B; Armstrong J
Radiother Oncol; 2003 Jan; 66(1):87-93. PubMed ID: 12559525
[TBL] [Abstract][Full Text] [Related]
55. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.
Hayman JA; Martel MK; Ten Haken RK; Normolle DP; Todd RF; Littles JF; Sullivan MA; Possert PW; Turrisi AT; Lichter AS
J Clin Oncol; 2001 Jan; 19(1):127-36. PubMed ID: 11134205
[TBL] [Abstract][Full Text] [Related]
56. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
[TBL] [Abstract][Full Text] [Related]
57. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
[TBL] [Abstract][Full Text] [Related]
58. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
59. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
Jaksic N; Chajon E; Bellec J; Corre R; Ricordel C; de Latour B; Lena H; Schick U; de Crevoisier R; Castelli J
Radiat Oncol; 2018 Aug; 13(1):147. PubMed ID: 30103774
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
